Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ans – page 81

1 400 clinical trials in Ans, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ans at a glance
1 400
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 400 trials in Ans

Open in trial search

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GAD20-209-FSP-A1
  • Sponsor:Nouscom S.r.l.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac amyloidosis

Not recruiting

Study on the Safety of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy Who Completed a Previous Trial

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Unicancer

Rectal cancer stage III+1

Not recruiting

Study of regorafenib and nivolumab with radiotherapy for patients with stage II-III rectal cancer before surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Nivolumab
  • Sponsor:Institut Jules Bordet

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Plasma cell myeloma

Not recruiting

Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study on the Effectiveness and Safety of Cisplatin, Carboplatin, Etoposide, and Durvalumab in Patients with Limited Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ans

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. The research explores innovative approaches to manage functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Acid Reflux Treatment

This primary care study evaluates different therapeutic approaches, including on-demand medication use and alternative treatment formulations, to improve patient outcomes in digestive health management.

02 Primary Care Innovation

Groundbreaking research in medication management strategies, specifically targeting long-term PPI use in primary care settings. The study compares various approaches to reduce unnecessary medication dependency.

  • Medication De-prescribing
  • Patient-Centered Care
  • Treatment Optimization

The research aims to establish more effective protocols for managing common digestive conditions while minimizing long-term medication use.

03 Therapeutic Alternatives

Investigation into alternative treatment options for managing heartburn and related gastrointestinal conditions. The study explores the effectiveness of different therapeutic approaches.

  • Alternative Treatments
  • Symptom Management
  • Treatment Comparison

This research evaluates the comparative effectiveness of various treatment strategies, including alginate formulations and flexible dosing schedules.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.